Clinical Trials Logo

MSI-H/dMMR Solid Tumors clinical trials

View clinical trials related to MSI-H/dMMR Solid Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT03736889 Recruiting - Clinical trials for MSI-H/dMMR Solid Tumors

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Start date: September 19, 2018
Phase: Phase 2
Study type: Interventional

In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).